GNPS - Carnitine Blood Plasma Samples- Acute and Chronic Stage - Positive Mode
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
ORGANISM(S): Trypanosoma Cruzi (ncbitaxon:5693) Mus Musculus (ncbitaxon:10090)
SUBMITTER: 
Laura-Isobel McCall
PROVIDER: MSV000084016 | GNPS | Thu Jun 27 13:16:00 BST 2019
REPOSITORIES: GNPS
Similar Datasets
Project description:Samples from mice infected and then treated with vehicle, carnitine or benznidazole in the chronic stage of infection. Tissue samples extracted with 50% methanol followed by 3:1 dichloromethane:methanol. C8 chromatography with negative mode data acquisition
2023-11-13 | MSV000093394 | MassIVE
Project description:Large intestine samples from mice infected with 50,000 Trypanosoma cruzi parasites or left uninfected. One week post-infection, mice were treated with carnitine, benznidazole or vehicle. Animals were euthanized after 10 days of treatment and organs collected. Metabolites were extracted with 50% methanol followed by 3:1 dichloromethane-methanol and analyzed by C8 chromatography, with positive mode ddMS2 data collection (data-dependent).
2020-03-24 | MSV000085142 | GNPS
Project description:Male C3H/HeJ mice were infected with 50,000 luciferase-expressing strain CL Brener trypanosoma cruzi parasites. Beginning 7 days post-infection, mice were treated with carnitine in drinking water (100 mg/kg/day dosing equivalent), benznidazole (100 mg/kg/day by intraperitoneal injection), or left untreated (vehicle group). One additional control group was uninfected. Mice were euthanized and liver and oesophagus collected at day 17 post-infection. Tissue was extracted with 50% methanol followed by 3:1 dichloromethane:methanol, and analyzed by C8 chromatography, with detection by MS in positive mode.
| MSV000084325 | GNPS
Project description:Large intestine samples from mice infected with 50,000 Trypanosoma cruzi parasites or left uninfected. One week post-infection, mice were treated with carnitine, benznidazole or vehicle. Animals were euthanized after 10 days of treatment and organs collected. Metabolites were extracted with 50% methanol followed by 3:1 dichloromethane-methanol and analyzed by C8 chromatography, with negative mode ddMS2 data collection (data-dependent).
2020-03-24 | MSV000085143 | GNPS
Project description:Heart Slices were extracted from mice and examined in positive mode on C8 column using Q Exactive LCMS untargeted run.
2019-04-05 | MSV000083665 | GNPS
Project description:Immunoglobulin diversity includes B-cell receptor, T-cell receptor, and antibody diversity. Existing studies focus more on the role of B-cell and T-cell receptor diversity in tumor immunity, while little is known about antibody diversity. This study examined and compared the blood exosomes of lung cancer patients and healthy individuals via proteomics and bioinformatics analyses. The results showed that of the 270 identified proteins, those enriched in the defense mechanism items were the most abundant. Most were antibody subtype molecules, accounting for 50.00%. Similarly, of the 40 identified exosomal DEPs, 29 were enriched in the defense mechanism items (72.50%), with a higher proportion of antibody subtypes (82.76%). Furthermore, 24 DEP antibody molecules were involved in 18 immune reaction-related signaling pathways. These results indicated that human serum exosomes contained a large number of antibody molecules, while the antibody subtypes from the lung cancer serum exosomes differed from those of the healthy controls. The variation in antibody diversity may be closely related to LA tumor immunity.
2025-05-07 | PXD054628 | Pride
Project description:Samples from mice infected and then treated with vehicle, carnitine or benznidazole in the chronic stage of infection. Tissue samples extracted with 50% methanol followed by 3:1 dichloromethane:methanol. C8 chromatography with negative mode data acquisition
2023-11-13 | MSV000093394 | GNPS
Project description:We sought to identify a usable biomarker from blood samples to characterize early-stage Alzheimer's disease (AD) patients, in order to facilitate rapid diagnosis, early therapeutic intervention, and monitoring of clinical trials. We compared metabolites from blood plasma in early-stage Alzheimer's disease patients with blood plasma from healthy controls using two different analytical platforms: Amino Acid Analyzer and Tandem Mass-Spectrometer. Early-stage Alzheimer's patient blood samples were obtained during an FDA-approved Phase IIa clinical trial (Clinicaltrial.gov NCT03062449). Participants included 25 early-stage Alzheimer's patients and 25 healthy controls in the United States. We measured concentrations of 2-aminoethyl dihydrogen phosphate and taurine in blood plasma samples. We found that plasma concentrations of a phospholipid metabolite, 2-aminoethyl dihydrogen phosphate, normalized by taurine concentrations, distinguish blood samples of patients with early-stage AD. This possible new Alzheimer's biomarker may supplement clinical diagnosis for early detection of the disease.
| S-EPMC9022864 | biostudies-literature
Project description:In the Netherlands, newborns are referred by the newborn screening (NBS) Program when a low free carnitine (C0) concentration (<5 μmol/l) is detected in their NBS dried blood spot. This leads to ~85% false positive referrals who all need an invasive, expensive and lengthy evaluation. We investigated whether a ratio of urine C0 / plasma C0 (RatioU:P) can improve the follow-up protocol for primary carnitine deficiency (PCD). A retrospective study was performed in all Dutch metabolic centres, using samples from newborns and mothers referred by NBS due to low C0 concentration. Samples were included when C0 excretion and plasma C0 concentration were sampled on the same day. RatioU:P was calculated as (urine C0 [μmol/mmol creatinine])/(plasma C0 [μmol/l]). Data were available for 59 patients with genetically confirmed PCD and 68 individuals without PCD. The RatioU:P in PCD patients was significantly higher (p value < 0.001) than in those without PCD, median [IQR], respectively: 3.4 [1.2-9.5], 0.4 [0.3-0.8], area under the curve (AUC) 0.837. Classified for age (up to 1 month) and without carnitine suppletion (PCD; N = 12, Non-PCD; N = 40), medians were 6.20 [4.4-8.8] and 0.37 [0.24-0.56], respectively. The AUC for RatioU:P was 0.996 with a cut-off required for 100% sensitivity at 1.7 (yielding one false positive case). RatioU:P accurately discriminates between positive and false positive newborn referrals for PCD by NBS. RatioU:P is less effective as a discriminative tool for PCD in adults and for individuals that receive carnitine suppletion.
| S-EPMC9830017 | biostudies-literature
Project description:BACKGROUND:Primary carnitine deficiency (PCD) is a disorder of fatty acid oxidation with a high prevalence in the Faroe Islands. Only patients homozygous for the c.95A>G (p.N32S) mutation have displayed severe symptoms in the Faroese patient cohort. In this study, we investigated carnitine levels in skeletal muscle, plasma, and urine as well as renal elimination kinetics before and after intermission with L-carnitine in patients homozygous for c.95A>G. METHODS:Five male patients homozygous for c.95A>G were included. Regular L-carnitine supplementation was stopped and the patients were observed during five days. Blood and urine were collected throughout the study. Skeletal muscle biopsies were obtained at 0, 48, and 96 h. RESULTS:Mean skeletal muscle free carnitine before discontinuation of L-carnitine was low, 158 nmol/g (SD 47.4) or 5.4% of normal. Mean free carnitine in plasma (fC0) dropped from 38.7 (SD 20.4) to 6.3 (SD 1.7) ?mol/L within 96 h (p?<?0.05). Mean T 1/2 following oral supplementation was approximately 9 h. Renal reabsorption of filtered carnitine following oral supplementation was 23%. The level of mean free carnitine excreted in urine correlated (R (2)?=?0.78, p?<?0.01) with fC0 in plasma. CONCLUSION:Patients homozygous for the c.95A>G mutation demonstrated limited skeletal muscle carnitine stores despite long-term high-dosage L-carnitine supplementation. Exacerbated renal excretion resulted in a short T 1/2 in plasma carnitine following the last oral dose of L-carnitine. Thus a treatment strategy of minimum three daily separate doses of L-carnitine is recommended, while intermission with L-carnitine treatment might prove detrimental.
| S-EPMC4375125 | biostudies-literature